66.9%), though this difference did not reach statistical significance (Figure 2B ).
← all excerpts
Long-term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma.
1
—
—
66.9%), though this difference did not reach statistical significance (Figure 2B ).